A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects with Malignant Solid Tumors that Express Nectin-4

Trial Identifier: AGS-22M6E-11-1
Sponsor: Astellas Pharma Inc.
Collaborator:
Agensys Inc.
Seattle Genetics, Inc.
NCTID:: NCT01409135
Start Date: June 2011
Primary Completion Date: April 2015
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
CA, Alberta Edmonton, Alberta, CA, T6G 1Z2
United States, CA San Francisco, CA, United States, 94115
United States, CO Aurora, CO, United States, 80045
United States, GA Atlanta, GA, United States, 30322
United States, MA Boston, MA, United States, 02115
United States, NC Chapel Hill, NC, United States, 27599
United States, NY Buffalo, NY, United States, 14263
USA, MI Detroit, MI, USA, 48201
USA, ny New York, ny, USA, 10021